Hospital

OneMedNet Announces CEO Succession Plan

Retrieved on: 
Tuesday, April 2, 2024
Cloud, Growth, OMN, Health, Real, Patient, Hospital, Change Healthcare, IPO, McKesson Corporation, Retirement, Division, Management

MINNEAPOLIS, April 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), the leading curator of regulatory-grade imaging Real World Data (“iRWD™”), today announced that its President, Aaron Green, has assumed the role of President and Chief Executive Officer, in addition to an appointment to OneMedNet’s Board of Directors. Mr. Green will succeed CEO, Paul Casey, who has announced his retirement and who will continue to serve on the Board of Directors.

Key Points: 
  • Mr. Green will succeed CEO, Paul Casey, who has announced his retirement and who will continue to serve on the Board of Directors.
  • As President and CEO, Green will lead all facets of OneMedNet’s business involving its iRWD™ offering, including R&D, product, strategy, and sales across global markets.
  • It is my privilege to hand over the reins to Aaron.”
    “I am honored to be named, and eager to assume the CEO position here at OneMedNet,” commented Green.
  • “The CEO transition from Paul to Aaron is a direct reflection of the Board’s mindful succession planning and our confidence that the Company will see continued operational momentum as Aaron assumes the role of CEO,” added Dr. Jeffrey Yu.

Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives

Retrieved on: 
Tuesday, April 2, 2024
Moses Austin, Ohio State University, Edwards Lifesciences, Education, Patient, Global strategy, SVP, Coronary thrombosis, Business development, Radiology, University, Doctors Hospital, Faculty, Senior, Abstract, MD Anderson Cancer Center, Hospital, MitraClip, Baptist Hospital, Interventional radiology, Health, Global marketing

IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.

Key Points: 
  • IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.
  • Dr. Niekamp will be instrumental in advancing Inari’s mission to improve patient care through physician education and new device development.
  • Mr. Benner joins Inari with more than 16 years of senior leadership experience with high-growth and transformational medical technology companies.
  • We are honored to add his talents to our Medical Affairs team,” said Dr. Thomas Tu, Chief Medical Officer of Inari.

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Retrieved on: 
Wednesday, April 3, 2024
Harvard Medical School, Dana–Farber Cancer Institute, GBM, Code, Glioblastoma, Clinical trial, Society, Brigham and Women's Hospital, Hospital, Tokyo Stock Exchange, ASCO, Neuro-Oncology (journal), Annual general meeting

LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago.

Key Points: 
  • LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago.
  • The oral presentation will be presented by one of the investigators of this clinical trial, Gilbert Youssef, M.D., Attending Physician at Harvard Medical School, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital.
  • The presentation details are as follows:

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Tuesday, April 2, 2024
Hospital, TMX Group, Teaching hospital, Phase, OTCQB, Liver

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The three new hospitals joining the Phase II study are Istanbul University-Cerrahpaşa, Sütçü İmam University Hospital in the city of Kahramanmaraş, and the Gazi University Hospital in Ankara, the capital of Turkey.
  • The trial now has a total of seven clinical sites across Turkey and Canada.

RadNet Announces Outpatient Radiology Partnership with Providence Health System to Include Seven Centers in Burbank, Santa Clarita and the Northern San Fernando Valley of Los Angeles

Retrieved on: 
Tuesday, April 2, 2024
San Fernando Valley, Partnership, Providence Health & Services, EMR, Patient, RadNet, Porter Ranch, Los Angeles, Record, Workflow, Health, Hospital

The new joint venture, Tri Valley Imaging Group, was established in conjunction with RadNet contributing four California imaging centers – two centers in Burbank and one each in Panorama City and Santa Clarita.

Key Points: 
  • The new joint venture, Tri Valley Imaging Group, was established in conjunction with RadNet contributing four California imaging centers – two centers in Burbank and one each in Panorama City and Santa Clarita.
  • Providence contributed three imaging centers to the joint venture located in Santa Clarita, Mission Hills and Porter Ranch.
  • “We are excited to expand our partnership with RadNet and leverage its expertise in imaging diagnostics,” said Karl Keeler, chief executive, Providence LA-San Fernando Valley Service Area.
  • “Through this new joint venture, we are furthering our shared vision of improving patient access to high quality imaging services across the San Fernando and Santa Clarita valleys.”

RAINN Welcomes HHS Action on Non-Consensual Pelvic Exams in America’s Teaching Hospitals

Retrieved on: 
Monday, April 1, 2024
RAINN, Patient, Public policy, Letter, Hospital, Light, HHS, Policy, Breast, Legislation, Nursing

“This letter from HHS is a critical leap forward in protecting patients and medical residents,” said Scott Berkowitz, president and founder of RAINN.

Key Points: 
  • “This letter from HHS is a critical leap forward in protecting patients and medical residents,” said Scott Berkowitz, president and founder of RAINN.
  • “Non-consensual sensitive exams are a shocking problem with a very simple solution: hospitals need to ask patients for consent, clearly and explicitly.
  • “Without consent, sensitive exams are a glaring violation of an anesthetized patient’s autonomy, whose body is being used for teaching purposes, without consent, in a vulnerable hospital setting,” said Stefan Turkheimer, vice president for public policy at RAINN.
  • “Requiring those in the medical profession to respect and obtain consent in all circumstances is a commitment to trauma-informed care and reinforces the importance of treating patients in a vulnerable setting with respect and dignity.”

TOMI Environmental Solutions, Inc. Reports Fourth Quarter and Year End 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
Hydrogen, MGH, Health, Hydrogen peroxide, Sale, Restaurant, Ionization, RELX, International, Webcast, Education, Harvard University, Food industry, GPO, Holiday, Global Biorisk Advisory Council, Academic Medical Center (Amsterdam), Police, Meat, Completion, Transport, Decontamination, Medication, AALAS, American Biological Safety Association, Research, Hospital, Food, ISSA, BIT, CES, Disinfectant, Conference, Horsepower, Growth, Assistant, MIT, Executive, School, Infection, DARPA, Environmental Health (journal), Raymond Castellani, Health care

FREDERICK, Md., April 01, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its fourth quarter and year end 2023 results.

Key Points: 
  • FREDERICK, Md., April 01, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its fourth quarter and year end 2023 results.
  • Financial Results for the year ended December 31, 2023, compared to December 31, 2022
    Total net revenue was $7,355,000 compared to $8,338,000.
  • Financial Results for the three months ended December 31, 2023, compared to December 31, 2022
    Total net revenue was $1,528,000 compared to $2,812,000.
  • TOMI will hold a conference call to discuss Fourth Quarter and year end 2023 results at 4:30 p.m.

VirTra Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, April 2, 2024
ERP, VBS, Hospital, Growth, STEP, Video game

CHANDLER, Ariz., April 01, 2024 (GLOBE NEWSWIRE) -- VirTra, Inc. (Nasdaq: VTSI) (“VirTra”), a global provider of judgmental use of force training simulators, firearms training simulators for the law enforcement and military markets, reported results for the fourth quarter and full year ended December 31, 2023. The financial statements are available on VirTra’s website and here.

Key Points: 
  • “2023 was a year of substantial transformation, which culminated in a strong fourth quarter with revenue of $10.1 million – our third double-digit million revenue quarter in 2023.
  • Operating income increased by $0.7 million to $2.6 million from $1.9 million in the fourth quarter of 2022.
  • Adjusted EBITDA, a non-GAAP metric, was $1.7 million, compared to $1.9 million in the fourth quarter of 2022.
  • “In the fourth quarter we continued to grow our revenue while making improvements to our profitability metrics,” said VirTra CFO Alanna Boudreau.

National Study: Ballad Health, ETSU Trauma Consolidation Saves Hundreds of Lives

Retrieved on: 
Monday, April 1, 2024
Trauma center, Level 3, Learning, Survival, Incidence, Partnership, Stunning, Ballad Health, Patient, Trauma, Research, Mortality, Lead, University, Death, Health, Injury, Johnson City Medical Center, Investment, Emergency medical services, Nursing, Patient safety, ICU, ETSU, Trauma Center, Physician, Rehabilitation, Hospital

In terms of lives, the reduction in the rate of deaths equates to hundreds of lives saved due to the successful consolidation of the region’s two Level 1 trauma centers.

Key Points: 
  • In terms of lives, the reduction in the rate of deaths equates to hundreds of lives saved due to the successful consolidation of the region’s two Level 1 trauma centers.
  • It found the patients with the highest likelihood of death due to severity had significantly improved survival rates post-consolidation.
  • Assisted by national experts, the advisory group recommended consolidation of the region’s two Level 1 trauma centers into one at Johnson City Medical Center, while maintaining Level 3 trauma services at Holston Valley Medical Center and Bristol Regional Medical Center.
  • “Excellent trauma care is a team effort from every corner of our region,” said Ballad Health Chairman and CEO Alan Levine.

Ultimate Medical Academy Celebrates Commencement for Thousands of Healthcare Student Graduates

Retrieved on: 
Monday, April 1, 2024
Friends, Marriage, Growth, Medicine, Education, Bureau, Interview, Careers New Zealand, Student, Ultimate Medical Academy, Yuengling Center, Medical assistant, Hospital, UMA, Purdue University, Nursing

The live-streamed ceremony honored students who completed or will complete their programs between October 23, 2023, and April 28, 2024.

Key Points: 
  • The live-streamed ceremony honored students who completed or will complete their programs between October 23, 2023, and April 28, 2024.
  • The event was live-streamed so UMA graduates, their friends and family members across the nation were able to join the celebration.
  • While commencement signifies the culmination of academic endeavors, UMA remains committed to supporting its graduates beyond graduation day.
  • These invaluable services extend throughout the professional journeys of all UMA alumni, ensuring their continued success in the evolving healthcare landscape.